Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 11, Issue 4, Pages 184-186Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2014.42
Keywords
-
Categories
Funding
- Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0409] Funding Source: researchfish
- Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0409] Funding Source: Medline
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
- Wellcome Trust [095691] Funding Source: Medline
- BBSRC [BBS/E/B/000C0409] Funding Source: UKRI
Ask authors/readers for more resources
Idelalisib, the first PI3K delta inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
